Jasper Therapeutics, Inc. — Form 8-K Summary
Business context and reporting period
This current report concerns executive appointments and a planned CFO departure, not a quarterly or annual financial-results period. The reported event date is September 23, 2026; the filing was signed September 28, 2026. Jasper Therapeutics is a Delaware corporation whose voting common stock trades on Nasdaq under JSPR.
Financial and operating information
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other operating-performance metrics, and no comparable-period financial data.
Management changes
- Herb Cross submitted his resignation on September 23, 2026, from CFO, Principal Financial Officer, Principal Accounting Officer, and Corporate Secretary roles, effective October 9, 2026, to pursue other professional endeavors.
- Effective upon Cross’s departure, CEO Jeet Mahal will serve as interim Principal Financial Officer; Vice President, Finance Rick Ruiz will serve as interim Principal Accounting Officer; and COO Matthew Ros will serve as interim Corporate Secretary.
- Ruiz joined Jasper in 2024 and has more than 25 years of finance experience, including SEC reporting. He will continue to receive an annual base salary of $364,000 and remain eligible for equity awards; he received no equity award in connection with the appointment.
Outlook, risks, and unusual items
The filing provides no financial guidance, business outlook, contingencies, or discussion of operating risks. It states that Ruiz has no family relationship with directors or other executive officers and that no arrangement or understanding with another person or entity led to his appointment.
Important facts to verify
- Confirm the October 9, 2026 effective date and interim officers’ start dates.
- Check subsequent filings for a permanent CFO appointment and any changes to the interim assignments.
- The filing refers to the COO as “Matthew Ros” in the appointment disclosure and “Mr. Ross” in the biography cross-reference; verify the correct spelling.
- Review the cited prior filings for background and compensation details of Mahal and the COO.